Skip to main content

Table 3 Selected clinical trial with immunotherapy for advanced HCC

From: Emerging therapies in advanced hepatocellular carcinoma

NCT number

Treatment

Target

Outcome

Phase

NCT02702401

Pembrolizumab vs best supportive care

PD-1

PFS, OS

Phase III

NCT02576509

Nivolumab vs sorafenib

PD-1

OS

Phase III

NCT02519348

Durvalumab + tremelimumab vs durvalumab monotherapy

PD-L1/CTLA-4

Adverse events

Phase II

NCT03298451

Durvalumab vs durvalumab + tremelimumab vs sorafenib

HIMALAYA

PD-L1/CTLA-4

OS

Phase III

NCT01658878

Nivolumab vs nivolumab + ipilimumab vs sorafenib

PD-L1/CTLA-4

ORR

Phase I/II

  1. PD-1 programmed cell death protein-1, PD-L1 programmed death-ligand 1, CTLA-4 cytotoxic T-lymphocyte-associated protein-4, OS overall survival, PFS progression free survival, ORR overall response rate